AC Immunity Shares Soar on Exclusive License Deal with Takeda
By Dean Seal
Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for Alzheimer's disease.
The stock was up 64% at $3.80 in premarket trading. Shares had fallen by more than 50% year-to-date when the market closed Friday.
The biopharmaceutical company said Monday morning that Takeda will receive an exclusive option to license global rights to ACT-24.060, AC Immune's active immunotherapy designed to delay or slow Alzheimer's disease progression.
AC Immune is set to receive an upfront payment of $100 million upon closing and be eligible for additional milestone payments of up to $2.1 billion.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 13, 2024 07:26 ET (11:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks